eligibility_summary
Adults 18–65 with aggressive NHL, survival ≥3 mo, relapsed/refractory after ≥1 line or PR after ≥4 cycles, measurable disease, ECOG 0–2, and adequate counts and renal/hepatic function. Exclude mitoxantrone, doxorubicin >360 mg/m2 (anthracycline eq), recent therapy or trial drugs, HSCT ≤100 d or CAR‑T, drug allergy, uncontrolled disease, cardiac disorders, active HBV/HCV/HIV, other malignancy, pregnant or no contraception, ≥G3 neuritis, CNS lymphoma, PI discretion.
trial_source
clinical_trials.gov from Dec 2, 2025
annotation_status
ai
ai_summary
Trial: Phase 2, single-arm GVM±R for relapsed/refractory aggressive NHL (DLBCL, PTCL). Interventions and mechanisms: • Mitoxantrone hydrochloride liposome – liposomal anthracenedione topoisomerase II inhibitor, intercalates DNA and induces double‑strand breaks, liposome aims to enhance tumor delivery and reduce cardiotoxicity. • Gemcitabine – antimetabolite deoxycytidine analog, inhibits ribonucleotide reductase and causes DNA chain termination (S‑phase cytotoxicity). • Vinorelbine – vinca alkaloid, binds β‑tubulin, blocks microtubule polymerization, causing mitotic arrest. • Anti‑CD20 monoclonal antibody (e.g., rituximab) – chimeric/humanized mAb, binds CD20 on B cells, mediating ADCC, complement lysis, and apoptosis. Targets: rapidly proliferating lymphoma cells (DNA replication and repair, nucleotide synthesis, mitotic spindle) and CD20+ malignant B cells via immune effector pathways.